Targeting PCSK9 for Hypercholesterolemia
- 6 January 2014
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 54 (1) , 273-293
- https://doi.org/10.1146/annurev-pharmtox-011613-140025
Abstract
Dyslipidemias are a predominant risk factor for cardiovascular disease. Biological and genetic research has led to the identification of several genes and proteins that may be pharmacologically targeted to improve lipoprotein profiles and possibly cardiovascular outcomes in patients with dyslipidemia. The observation that proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates the levels of circulating low-density lipoprotein C (LDL-C) by enhancing the degradation of the hepatic low-density lipoprotein receptor (LDLR) prompted the search for drugs that inhibit PCSK9 activity. Several approaches to inhibiting PCSK9 activity have been proposed; these involve inhibitory antibodies, small molecules, and gene silencing. To date, the most promising and advanced approach relates to monoclonal antibodies, which can decrease LDL cholesterol by 65–70%, even as an add-on therapy to a maximal dose of a statin. Phase III studies and large, event-driven clinical trials are ongoing and will fully address the viability and role of these drugs in clinical practice.Keywords
This publication has 107 references indexed in Scilit:
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese peopleTranslational Research, 2011
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences, 2009
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorProceedings of the National Academy of Sciences, 2008
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesProceedings of the National Academy of Sciences, 2008
- PCSK9 is required for the disposal of non‐acetylated intermediates of the nascent membrane protein BACE1EMBO Reports, 2008
- Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading ActivityBiochemistry, 2008
- The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domainProceedings of the National Academy of Sciences, 2007
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiationProceedings of the National Academy of Sciences, 2003